8-K: Milestone Pharmaceuticals Receives Complete Response Letter from FDA for Etripamil Nasal Spray

The FDA issued a Complete Response Letter (CRL) for Milestone Pharmaceuticals' New Drug Application (NDA) for CARDAMYST (etripamil) nasal spray, citing Chemistry, Manufacturing and Controls (CMC) issues but no clinical concerns.

Summary

• Milestone Pharmaceuticals announced that the FDA issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for CARDAMYST (etripamil) nasal spray.
• The CRL focused on Chemistry, Manufacturing and Controls (CMC) issues, specifically regarding nitrosamine impurities and an inspection of a facility performing release testing.
• The FDA did not raise any concerns regarding the clinical safety or efficacy data of etripamil.
• Milestone Pharmaceuticals plans to request a Type A meeting with the FDA to discuss the issues raised in the CRL and intends to resubmit the NDA.
• As of December 31, 2024, Milestone Pharmaceuticals had $69.7 million in cash, cash equivalents, and short-term investments.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the CRL from the FDA, which delays potential approval. However, the absence of clinical concerns and the company's intent to address the CMC issues provide some optimism.

Positives

• The FDA did not raise any concerns regarding the clinical safety or efficacy data of etripamil.
• Milestone Pharmaceuticals has $69.7 million in cash, cash equivalents, and short-term investments as of December 31, 2024.
• Milestone Pharmaceuticals intends to request a Type A meeting with the FDA to discuss the issues raised in the CRL and intends to resubmit the NDA.

Negatives

• The FDA issued a Complete Response Letter (CRL) for the NDA for CARDAMYST (etripamil) nasal spray.
• The CRL focused on Chemistry, Manufacturing and Controls (CMC) issues, specifically regarding nitrosamine impurities and an inspection of a facility performing release testing.

Risks

• The company needs to address the CMC issues raised by the FDA, including providing additional information on nitrosamine impurities and ensuring the release testing facility is compliant with Current Good Manufacturing Practices.
• There is a risk that future interactions with the FDA may not have satisfactory outcomes.
• The NDA for etripamil may not be approved by the FDA, or approval may be delayed.
• Clinical trials may not validate the safety and efficacy of etripamil for PSVT or other indications.

Future Outlook

Milestone Pharmaceuticals intends to request a Type A meeting with the FDA to discuss the issues raised in the CRL and plans to resubmit the NDA for etripamil.

Management Comments

• Joe Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals, stated that the company is deeply disappointed by the CRL but remains committed to the potential of CARDAMYST.
• Management is confident they can collaborate with the FDA to address the issues in a resubmission.

Industry Context

The CRL highlights the increasing scrutiny by regulatory agencies on manufacturing processes and quality control, particularly regarding impurities like nitrosamines, which have been a concern across the pharmaceutical industry.

Comparison to Industry Standards

• The FDA's focus on CMC issues, particularly nitrosamine impurities, aligns with increased regulatory scrutiny across the pharmaceutical industry.
• Other companies developing nasal spray products, such as Optinose with XHANCE, have also faced regulatory hurdles related to manufacturing and clinical data.
• The $69.7 million cash position provides Milestone with runway to address the FDA's concerns and potentially resubmit the NDA, but the timeline and cost of remediation are uncertain.

Stakeholder Impact

• Shareholders may experience a negative impact due to the delay in potential approval and the need for further investment to address the FDA's concerns.
• Patients with PSVT may experience a delay in access to a potential new treatment option.
• Employees may face uncertainty as the company navigates the regulatory challenges.

Next Steps

• Milestone Pharmaceuticals intends to request a Type A meeting with the FDA.
• The company will address the CMC issues raised in the CRL.
• Milestone Pharmaceuticals plans to resubmit the NDA for etripamil.

Key Dates

Keywords

etripamil, CARDAMYST, FDA, Complete Response Letter, PSVT, Milestone Pharmaceuticals, NDA, CMC, nitrosamine impurities, Type A meeting